Andrew Kruegel, Kures president and co-founder (Columbia Tech Ventures via Vimeo)
After psilocybin and ketamine, a new biotech comes along developing a drug Scott Gottlieb fought
Andrew Kruegel was six years into his chemistry work at Columbia University, when, one day in August 2016, he learned he might have only 30 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
